These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 16361845)

  • 1. A critical assessment of uremia research.
    Locatelli F; Di Filippo S; Pozzoni P
    Blood Purif; 2006; 24(1):71-6. PubMed ID: 16361845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can convective therapies improve dialysis outcomes?
    Locatelli F; Manzoni C; Cavalli A; Di Filippo S
    Curr Opin Nephrol Hypertens; 2009 Nov; 18(6):476-80. PubMed ID: 19726986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Convective therapies for removal of middle molecular weight uremic toxins in end-stage renal disease: a review of the evidence.
    Thomas G; Jaber BL
    Semin Dial; 2009; 22(6):610-4. PubMed ID: 20017830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Uremic Toxins: how can we improve the removal today?].
    Teatini U; Romei Longhena G
    G Ital Nefrol; 2017 Sep; 34(5):89-101. PubMed ID: 28963830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Do convective treatments significantly reduce morbidity and mortality?].
    Manzoni C; Cavalli A; Pontoriero G; Di Filippo S; Locatelli F
    G Ital Nefrol; 2009; 26 Suppl 45():S16-9. PubMed ID: 19382089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [On-line HFR and removal of uremic toxins inducing the loss of phospholipidic asymmetry of the erythrocyte membrane].
    Sirolli V; Cappelli P; Amoroso L; Di Liberato L; Muscianese P; Santarelli P; Del Rosso G; Bonomini M
    G Ital Nefrol; 2004; 21 Suppl 30():S208-11. PubMed ID: 15750987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resolving controversies regarding hemodiafiltration versus hemodialysis: the Dutch Convective Transport Study.
    Penne EL; Blankestijn PJ; Bots ML; van den Dorpel MA; Grooteman MP; Nubé MJ; ter Wee PM;
    Semin Dial; 2005; 18(1):47-51. PubMed ID: 15663765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cystatin C, beta2-microglobulin and C-reactive protein in hemodiafiltration and on-line endogenous liquid reinfusion and in low flux polysulphone bicarbonate conventional hemodialysis].
    Cristofano C; Vernaglione L; Perniola MA; Lo Barco C; Muscogiuri P; Chimienti S
    G Ital Nefrol; 2004; 21 Suppl 30():S197-200. PubMed ID: 15750984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in beta2-microglobulin with super-flux versus high-flux dialysis membranes: results of a 6-week, randomized, double-blind, crossover trial.
    Pellicano R; Polkinghorne KR; Kerr PG
    Am J Kidney Dis; 2008 Jul; 52(1):93-101. PubMed ID: 18423807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On-line hemodiafiltration: technique and efficiency.
    Pedrini LA
    J Nephrol; 2003; 16 Suppl 7():S57-63. PubMed ID: 14733302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pro convection: are convective therapies like hemodiafiltration and hemofiltration the future of extracorporeal blood purification?].
    Bolasco PG
    G Ital Nefrol; 2008; 25(4):389-95. PubMed ID: 18663685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Online hemodiafiltration.
    Van Laecke S; De Wilde K; Vanholder R
    Artif Organs; 2006 Aug; 30(8):579-85. PubMed ID: 16911311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Aspects of the on-line hemodiafiltration with regeneration and reinfusion of the ultrafiltrate (HFR): multicenter study].
    De Simone W; De Simone M; De Simone A; Iannaccone S; Manganelli R; Zito B; Guastaferro P; Apperti V; Paglionico C; Salvati G; Veniero P; Ferro F; Tedesco V
    G Ital Nefrol; 2004; 21 Suppl 30():S161-7. PubMed ID: 15750977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Renal replacement therapy by hemodialysis: an overview].
    Jacobs C
    Nephrol Ther; 2009 Jul; 5(4):306-12. PubMed ID: 19481513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. More of the same: improving outcomes through intensive hemodialysis.
    McFarlane PA
    Semin Dial; 2009; 22(6):598-602. PubMed ID: 20017828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The MPO Study: just a European HEMO Study or something very different?
    Locatelli F; Gauly A; Czekalski S; Hannedouche T; Jacobson SH; Loureiro A; Martin-Malo A; Papadimitriou M; Passlick-Deetjen J; Ronco C; Vanholder R; Wizemann V;
    Blood Purif; 2008; 26(1):100-4. PubMed ID: 18182806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acetate free biofiltration (AFB): from theory to clinical results.
    Galli G; Panzetta G
    Clin Nephrol; 1998 Jul; 50(1):28-37. PubMed ID: 9710344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Depurative efficiency of intermediate and large molecules with different hemodialysis modalities].
    Maduell F
    Nefrologia; 2005; 25 Suppl 2():15-8. PubMed ID: 16050396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Acute biocompatibility of hemodiafiltration with endogenous reinfusion (HFR)].
    Aucella F; Gesuete A; Sereni L; Netti S; Savastano AM; Querques M; Specchio A; De Min A; Avanzi C; Montemurno C; Grandone E; Cappucci F; Procaccini DA; Stallone C; Gesualdo L;
    G Ital Nefrol; 2004; 21 Suppl 30():S185-9. PubMed ID: 15750982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.